Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
(NASDAQ: KOD) Delayed: 36.63 --0 (-0%)
Previous Close $36.63    52 Week High $ 
Open $36.63    52 Week Low $ 
Day High $36.63    P/E N/A 
Day Low $36.63    EPS $ 
Volume 1